183 related articles for article (PubMed ID: 19173282)
1. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.
Kawaguchi Y; Miyamoto Y; Inoue T; Kaneda Y
Int J Cancer; 2009 May; 124(10):2478-87. PubMed ID: 19173282
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis in hormone-resistant human prostate cancer PC3 cells by inactivated Sendai virus.
Gao H; Gong XC; Chen ZD; Xu XS; Zhang Q; Xu XM
Biomed Environ Sci; 2014 Jul; 27(7):506-14. PubMed ID: 25073909
[TBL] [Abstract][Full Text] [Related]
3. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles.
Matsushima-Miyagi T; Hatano K; Nomura M; Li-Wen L; Nishikawa T; Saga K; Shimbo T; Kaneda Y
Clin Cancer Res; 2012 Nov; 18(22):6271-83. PubMed ID: 23014529
[TBL] [Abstract][Full Text] [Related]
4. IPS-1 plays a dual function to directly induce apoptosis in murine melanoma cells by inactivated Sendai virus.
Zhang Q; Xu X; Yuan Y; Gong X; Chen Z; Xu X
Int J Cancer; 2014 Jan; 134(1):224-34. PubMed ID: 23784981
[TBL] [Abstract][Full Text] [Related]
5. Inactivated Sendai Virus Induces ROS-dependent Apoptosis and Autophagy in Human Prostate Cancer Cells.
Qian M; Tan HM; Yu N; Wang T; Zhang Q
Biomed Environ Sci; 2018 Apr; 31(4):280-289. PubMed ID: 29773091
[TBL] [Abstract][Full Text] [Related]
6. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon.
Tanaka M; Shimbo T; Kikuchi Y; Matsuda M; Kaneda Y
Int J Cancer; 2010 Apr; 126(8):1982-1991. PubMed ID: 19830690
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.
Fujita K; Nakai Y; Kawashima A; Ujike T; Nagahara A; Nakajima T; Inoue T; Lee CM; Uemura M; Miyagawa Y; Kaneda Y; Nonomura N
Cancer Gene Ther; 2017 Jul; 24(7):277-281. PubMed ID: 28497777
[TBL] [Abstract][Full Text] [Related]
8. An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis.
Liu LW; Nishikawa T; Kaneda Y
Mol Ther; 2016 Feb; 24(1):135-45. PubMed ID: 26548591
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
Takehara Y; Satoh T; Nishizawa A; Saeki K; Nakamura M; Masuzawa M; Kaneda Y; Katayama I; Yokozeki H
Clin Immunol; 2013 Oct; 149(1):1-10. PubMed ID: 23886549
[TBL] [Abstract][Full Text] [Related]
10. Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells.
Li S; Nishikawa T; Kaneda Y
Cancer Sci; 2017 Dec; 108(12):2333-2341. PubMed ID: 28945328
[TBL] [Abstract][Full Text] [Related]
11. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
Kurooka M; Kaneda Y
Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703
[TBL] [Abstract][Full Text] [Related]
12. A biomimetic approach to hormone resistant prostate cancer cell isolation using inactivated Sendai virus (HVJ-E).
Okada T; Uto K; Aoyagi T; Ebara M
Biomater Sci; 2016 Jan; 4(1):96-103. PubMed ID: 26553555
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-γ production.
Saga K; Tamai K; Yamazaki T; Kaneda Y
Clin Cancer Res; 2013 Feb; 19(3):668-79. PubMed ID: 23251005
[TBL] [Abstract][Full Text] [Related]
14. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.
Kawano H; Komaba S; Kanamori T; Kaneda Y
BMC Med; 2007 Sep; 5():28. PubMed ID: 17883878
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
Fujihara A; Kurooka M; Miki T; Kaneda Y
Cancer Immunol Immunother; 2008 Jan; 57(1):73-84. PubMed ID: 17602226
[TBL] [Abstract][Full Text] [Related]
16. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope.
Matsuda M; Yamamoto T; Matsumura A; Kaneda Y
Gene Ther; 2009 Dec; 16(12):1465-76. PubMed ID: 19675593
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.
Tanemura A; Kiyohara E; Katayama I; Kaneda Y
Cancer Gene Ther; 2013 Nov; 20(11):599-605. PubMed ID: 24157924
[TBL] [Abstract][Full Text] [Related]
18. [Anticancer immunotherapy using inactivated Sendai virus particles].
Kurooka M; Kaneda Y
Uirusu; 2007 Jun; 57(1):19-27. PubMed ID: 18040151
[TBL] [Abstract][Full Text] [Related]
19. 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma.
Nomura M; Shimbo T; Miyamoto Y; Fukuzawa M; Kaneda Y
Cancer Sci; 2013 Feb; 104(2):238-44. PubMed ID: 23134437
[TBL] [Abstract][Full Text] [Related]
20. Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity.
Chang CY; Tai JA; Li S; Nishikawa T; Kaneda Y
Oncotarget; 2016 Jul; 7(27):42195-42207. PubMed ID: 27259252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
